Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-27T09:21:10.959Z Has data issue: false hasContentIssue false

5 - DNA methylation

from Part 1.1 - Analytical techniques: analysis of DNA

Published online by Cambridge University Press:  05 February 2015

Marsha Reyngold
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Timothy A. Chan
Affiliation:
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Edward P. Gelmann
Affiliation:
Columbia University, New York
Charles L. Sawyers
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York
Frank J. Rauscher, III
Affiliation:
The Wistar Institute Cancer Centre, Philadelphia
Get access

Summary

Introduction

Epigenetic modifications cause heritable changes in the expression of the genome without changes in the primary DNA sequence. Epigenetics play an important role in normal development, and epigenetic aberrations have been implicated in a number of human diseases, including cancer. In mammalian cells, two primary mechanisms mold the epigenetic landscape – DNA methylation and histone modifications. The focus of this chapter is to summarize the role of DNA methylation in cancer development and progression.

The importance of DNA methylation

In eukaryotes, DNA methylation is most often found on the 5ʹ position of cytosine bases that are part of CpG dinucleotides (m5C). All types of DNA sequences, including genes, intergenic DNA, and repetitive sequences, are targets of methylation. In normal cells, there is generally a paucity of methylation in regions called CpG islands (CGIs), which are stretches of sequence enriched in CpG dinucleotides. These are often preferentially located in the 5ʹ regions of genes. CpG dinucleotides have been progressively depleted from the eukaryotic genome over the course of evolution, and constitute about 1–2% of mammalian sequences (1). About 70% of the remaining CpG dinucleotides in the mammalian genome are methylated (2). This methylation is thought to play an important role in the co-ordination of chromosomal structure and integrity, and facilitating the functional segregation of active and silent chromatin. Repetitive sequences such as Alu repeats and transposons are frequently heavily methylated, and this state may serve to maintain a transcriptionally repressed state in these regions (3,4).

Type
Chapter
Information
Molecular Oncology
Causes of Cancer and Targets for Treatment
, pp. 37 - 45
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ng, HH, Bird, A. DNA methylation and chromatin modification. Current Opinion in Genetic Development 1999;9:158–63.CrossRef
Ehrlich, M, Gama-Sosa, MA, Huang, LH, et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Research 1982;10:2709–21.CrossRef
Bestor, TH, Tycko, B. Creation of genomic methylation patterns. Nature Genetics 1996;12:363–7.CrossRef
Szpakowski, S, Sun, X, Lage, JM, et al. Loss of epigenetic silencing in tumors preferentially affects primate-specific retroelements. Gene 2009; 448:151–67.CrossRef
Antequera, F, Bird, A. Number of CpG islands and genes in human and mouse. Proceedings of the National Academy of Sciences USA 1993;90:11 995–9.
Bird, AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321:209–13.CrossRef
Bird, AP, Wolffe, AP. Methylation-induced repression: belts, braces, and chromatin. Cell 1999;99:451–4.CrossRef
Jones, PL, Veenstra, GJ, Wade, PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nature Genetics 1998;19:187–91.CrossRef
Straussman, R, Nejman, D, Roberts, D, et al. Developmental programming of CpG island methylation profiles in the human genome. Nature Structural and Molecular Biology 2009;16:564–71.CrossRef
Diaz-Meyer, N, Yang, Y, Sait, SN, Maher, ER, Higgins, MJ.Alternative mechanisms associated with silencing of CDKN1C in Beckwith–Wiedemann syndrome. Journal of Medical Genetics 2005;42:648–55.CrossRefGoogle ScholarPubMed
Horsthemke, B, Buiting, K. Imprinting defects on human chromosome 15. Cytogenetic and Genome Research 2006;113:292–9.CrossRef
Ohlsson, R, Nystrom, A, Pfeifer-Ohlsson, S, et al. IGF2 is parentally imprinted during human embryogenesis and in the Beckwith–Wiedemann syndrome. Nature Genetics 1993;4:94–7.CrossRef
Weksberg, R, Shen, DR, Fei, YL, Song, QL, Squire, J. Disruption of insulin-like growth factor 2 imprinting in Beckwith–Wiedemann syndrome. Nature Genetics 1993;5:143–50.CrossRef
Herman, JG, Baylin, SB.Gene silencing in cancer in association with promoter hypermethylation. New England Journal of Medicine. 2003;349:2042–54.CrossRefGoogle ScholarPubMed
Jones, PA, Baylin, SB. The epigenomics of cancer. Cell 2007;128:683–92.CrossRef
Laird, PW. Oncogenic mechanisms mediated by DNA methylation. Molecular Medicine Today 1997;3:223–9.CrossRef
Wajed, SA, Laird, PW, DeMeester, TR. DNA methylation: an alternative pathway to cancer. Annals of Surgery 2001;234:10–20.CrossRef
Hellman, A, Chess, A. Gene body-specific methylation on the active X chromosome. Science 2007;315:1141–3.CrossRef
Goll, MG, Bestor, TH. Eukaryotic cytosine methyltransferases. Annual Review of Biochemistry 2005;74:481–514.CrossRef
Okano, M, Bell, DW, Haber, DA, Li, E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999;99:247–57.CrossRef
Wu, SC, Zhang, Y. Active DNA demethylation: many roads lead to Rome. Nature Reviews Molecular and Cellular Biology 2010;11:607–20.CrossRef
Tahiliani, M, Koh, KP, Shen, Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009;324:930–5.CrossRef
He, YF, Li, BZ, Li, Z, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011;333:1303–7.CrossRef
Esteller, M.Epigenetics in cancer. New England Journal of Medicine 2008;358:1148–59.CrossRefGoogle Scholar
Liang, G, Lin, JC, Wei, V, et al. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proceedings of the National Academy of Sciences USA 2004;101:7357–62.CrossRef
Bannister, AJ, Schneider, R, Myers, FA, et al. Spatial distribution of di- and tri-methyl lysine 36 of histone H3 at active genes. Journal of Biological Chemistry 2005;280:17 732–6.CrossRefGoogle ScholarPubMed
Singer, MS, Kahana, A, Wolf, AJ, et al. Identification of high-copy disruptors of telomeric silencing in Saccharomyces cerevisiae. Genetics 1998;150:613–32.
Ng, HH, Ciccone, DN, Morshead, KB, Oettinger, MA, Struhl, K. Lysine-79 of histone H3 is hypomethylated at silenced loci in yeast and mammalian cells: a potential mechanism for position-effect variegation. Proceedings of the National Academy of Sciences USA 2003;100:1820–5.CrossRef
Peters, AH, Mermoud, JE, O’Carroll, D, et al. Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin. Nature Genetics 2002;30:77–80.CrossRef
Peters, AH, Kubicek, S, Mechtler, K, et al. Partitioning and plasticity of repressive histone methylation states in mammalian chromatin. Molecular Cell 2003;12:1577–89.CrossRef
Sims, JK, Houston, SI, Magazinnik, T, Rice, JC.A trans-tail histone code defined by monomethylated H4 Lys-20 and H3 Lys-9 demarcates distinct regions of silent chromatin. Journal of Biological Chemistry 2006;281:12 760–6.CrossRefGoogle ScholarPubMed
Fuks, F, Hurd, PJ, Wolf, D, et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. Journal of Biological Chemistry 2003;278:4035–40.CrossRefGoogle ScholarPubMed
Vire, E, Brenner, C, Deplus, R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439:871–4.CrossRef
Feinberg, AP, Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89–92.CrossRef
Oshimo, Y, Nakayama, H, Ito, R, et al. Promoter methylation of cyclin D2 gene in gastric carcinoma. International Journal of Oncology 2003;23:1663–70.Google ScholarPubMed
Wilson, AS, Power, BE, Molloy, PL. DNA hypomethylation and human diseases. Biochimica et Biophysica Acta 2007;1775:138–62.
Wu, H, Chen, Y, Liang, J, et al. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 2005;438:981–7.CrossRef
Hoffmann, MJ, Schulz, WA. Causes and consequences of DNA hypomethylation in human cancer. Biochemistry and Cell Biology 2005;83:296–321.CrossRef
Howard, G, Eiges, R, Gaudet, F, Jaenisch, R, Eden, A. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 2008;27:404–8.CrossRef
Gaudet, F, Hodgson, JG, Eden, A, et al. Induction of tumors in mice by genomic hypomethylation. Science 2003;300:489–92.CrossRef
Gu, M, Kim, D, Bae, Y, et al. Analysis of microsatellite instability, protein expression and methylation status of hMLH1 and hMSH2 genes in gastric carcinomas. Hepatogastroenterology 2009;56:899–904.
Herman, JG, Latif, F, Weng, Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proceedings of the National Academy of Sciences USA 1994;91:9700–4.CrossRef
Jacinto, FV, Esteller, M. Mutator pathways unleashed by epigenetic silencing in human cancer. Mutagenesis 2007;22:247–53.CrossRef
Kane, MF, Loda, M, Gaida, GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Research 1997;57:808–11.
Merlo, A, Herman, JG, Mao, L, et al. 5’ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Medicine 1995;1:686–92.CrossRef
Esteller, M, Garcia-Foncillas, J, Andion, E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New England Journal of Medicine 2000;343:1350–4.CrossRefGoogle ScholarPubMed
Esteller, M, Silva, JM, Dominguez, G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. Journal of the National Cancer Institute 2000;92:564–9.CrossRefGoogle ScholarPubMed
Greger, V, Passarge, E, Hopping, W, Messmer, E, Horsthemke, B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Human Genetics 1989;83:155–8.CrossRef
Toyota, M, Ahuja, N, Ohe-Toyota, M, et al. CpG island methylator phenotype in colorectal cancer. Proceedings of the National Academy of Sciences USA 1999;96:8681–6.CrossRef
Toyota, M, Ohe-Toyota, M, Ahuja, N, Issa, JP. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proceedings of the National Academy of Sciences USA 2000;97:710–15.CrossRef
Weisenberger, DJ, Siegmund, KD, Campan, M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nature Genetics 2006;38:787–93.CrossRef
van Rijnsoever, M, Grieu, F, Elsaleh, H, Joseph, D, Iacopetta, B. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 2002;51:797–802.CrossRef
Oue, N, Motoshita, J, Yokozaki, H, et al. Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas. Journal of Pathology 2002;198:55–9.CrossRefGoogle ScholarPubMed
TCGA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways (Cancer Genome Atlas Network). Nature 2008;455:1061–8.CrossRef
Noushmehr, H, Weisenberger, DJ, Diefes, K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17:510–22.CrossRef
Fang, F, Turcan, S, Rimner, A, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Science Translational Medicine 2011;3:75ra25.
Ogino, S, Nosho, K, Kirkner, GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90–6.CrossRef
Ogino, S, Meyerhardt, JA, Kawasaki, T, et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Archiv 2007;450:529–37.CrossRef
Issa, JP. Colon cancer: it's CIN or CIMP. Clinical Cancer Research 2008;14:5939–40.CrossRef
Ley, TJ, Ding, L, Walter, MJ, et al. DNMT3A mutations in acute myeloid leukemia. New England Journal of Medicine 2010;363:2424–33.CrossRefGoogle ScholarPubMed
Yan, XJ, Xu, J, Gu, ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nature Genetics 2011;43:309–15.CrossRef
Girault, I, Tozlu, S, Lidereau, R, Bieche, I. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clinical Cancer Research 2003;9:4415–22.
Ahluwalia, A, Hurteau, JA, Bigsby, RM, Nephew, KP. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecologic Oncology 2001;82:299–304.
Abdel-Wahab, O, Mullally, A, Hedvat, C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009;114:144–7.CrossRef
Figueroa, ME, Abdel-Wahab, O, Lu, C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553–67.CrossRef
Fraga, MF, Ballestar, E, Villar-Garea, A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genetics 2005;37:391–400.CrossRef
Varambally, S, Dhanasekaran, SM, Zhou, M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624–9.CrossRef
Kleer, CG, Cao, Q, Varambally, S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences USA 2003;100:11606–11.CrossRef
Kidani, K, Osaki, M, Tamura, T, et al. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncology 2009;45:39–46.CrossRef
Figueroa, ME, Abdel-Wahab, O, Lu, C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553–67.CrossRef
Pasqualucci, L, Dominguez-Sola, D, Chiarenza, A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011;471:189–95.CrossRef
van Haaften, G, Dalgliesh, GL, Davies, H, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature Genetics 2009;41:521–3.CrossRef
Parsons, DW, Li, M, Zhang, X, et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011;331:435–9.CrossRef
Gui, Y, Guo, G, Huang, Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature Genetics 2011;43:875–8.CrossRef
Eads, CA, Danenberg, KD, Kawakami, K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Research 2000;28:E32.
Meissner, A, Mikkelsen, TS, Gu, H, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008;454:766–70.CrossRef
Herman, JG, Graff, JR, Myohanen, S, Nelkin, BD, Baylin, SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of the National Academy of Sciences USA 1996;93:9821–6.CrossRef
Ehrich, M, Nelson, MR, Stanssens, P, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proceedings of the National Academy of Sciences USA 2005;102:15 785–90.
Uhlmann, K, Brinckmann, A, Toliat, MR, Ritter, H, Nurnberg, P. Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis. Electrophoresis 2002;23:4072–9.CrossRef
Fraga, MF, Esteller, M. DNA methylation: a profile of methods and applications. Bio Techniques 2002;33:632, 4, 6–49.
Esteller, M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Reviews Genetics 2007;8:286–98.CrossRef
Weber, M, Davies, JJ, Wittig, D, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nature Genetics 2005;37:853–62.CrossRef
Keshet, I, Schlesinger, Y, Farkash, S, et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nature Genetics 2006;38:149–53.CrossRef
Zhang, X, Yazaki, J, Sundaresan, A, et al. Genome-wide high-resolution mapping and functional analysis of DNA methylation in arabidopsis. Cell 2006;126:1189–201.CrossRef
Schumacher, A, Kapranov, P, Kaminsky, Z, et al. Microarray-based DNA methylation profiling: technology and applications. Nucleic Acids Research 2006;34:528–42.CrossRef
Khulan, B, Thompson, RF, Ye, K, et al. Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome Research 2006;16:1046–55.CrossRef
Lister, R, Pelizzola, M, Dowen, RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009;462:315–22.CrossRef
Jacinto, FV, Ballestar, E, Esteller, M. Methyl-DNA immunoprecipitation (MeDIP): hunting down the DNA methylome. BioTechniques 2008;44:35, 7, 9 passim.
Serre, D, Lee, BH, Ting, AH. MBD-isolated genome sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome. Nucleic Acids Research 2010;38:391–9.CrossRef
Down, TA, Rakyan, VK, Turner, DJ, et al. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Nature Biotechnology 2008;26:779–85.CrossRef
Brock, MV, Hooker, CM, Ota-Machida, E, et al. DNA methylation markers and early recurrence in stage I lung cancer. New England Journal of Medicine 2008;358:1118–28.CrossRefGoogle ScholarPubMed
Hegi, ME, Diserens, AC, Gorlia, T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine 2005;352:997–1003.CrossRefGoogle ScholarPubMed
Chaudhry, P, Srinivasan, R, Patel, FD. Utility of gene promoter methylation in prediction of response to platinum-based chemotherapy in epithelial ovarian cancer (EOC). Cancer Investigation 2009;27:877–84.CrossRef
Fukushima, T, Katayama, Y, Watanabe, T, et al. Promoter hypermethylation of mismatch repair gene hMLH1 predicts the clinical response of malignant astrocytomas to nitrosourea. Clinical Cancer Research 2005;11:1539–44.CrossRef
Thibodeau, SN, Bren, G, Schaid, D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816–19.CrossRef
Goel, A, Nagasaka, T, Arnold, CN, et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 2007;132:127–38.CrossRef

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×